Xavier Thomas
Overview
Explore the profile of Xavier Thomas including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
288
Citations
7458
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Cannas G, Poutrel S, Heiblig M, Labussiere H, Larcher M, Thomas X, et al.
Ann Hematol
. 2023 Jun;
102(7):1657-1667.
PMID: 37269388
Population-based studies and case reports suggest that there may be an increased risk of acute leukemia associated with sickle cell disease (SCD). Following the description of a new case report,...
12.
Orvain C, Chantepie S, Thomas X, Escofrre-Barbe M, Huguet F, Desbrosses Y, et al.
Haematologica
. 2023 Mar;
108(12):3287-3297.
PMID: 36891751
Whereas the prognosis of adult patients with Philadelphia-negative acute lymphoblastic leukemia (ALL) has greatly improved since the advent of pediatric-inspired regimens, the impact of initial central nervous system (CNS) involvement...
13.
de Botton S, Fenaux P, Yee K, Recher C, Wei A, Montesinos P, et al.
Blood Adv
. 2023 Feb;
7(13):3117-3127.
PMID: 36724515
Olutasidenib (FT-2102) is a potent, selective, oral, small-molecule inhibitor of mutant isocitrate dehydrogenase 1 (mIDH1). Overall, 153 IDH1 inhibitor-naive patients with mIDH1R132 relapsed/refractory (R/R) acute myeloid leukemia (AML) received olutasidenib...
14.
Thomas X
Expert Opin Investig Drugs
. 2022 Dec;
32(1):37-52.
PMID: 36541671
Introduction: Despite advances in treatment approaches in acute lymphoblastic leukemia (ALL), the prognosis of adults with newly diagnosed T-ALL remains poor, as well as that of adults and children with...
15.
Le Meur G, Plesa A, Larcher M, Fossard G, Barraco F, Loron S, et al.
Transplant Cell Ther
. 2022 Sep;
29(1):38.e1-38.e9.
PMID: 36108977
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) after conditioning with a sequential association of fludarabine, amsacrine, and cytosine arabinoside (FLAMSA) followed by a reduced-intensity conditioning regimen has emerged for patients with...
16.
Thomas X, Elhamri M, Deloire A, Heiblig M
Expert Opin Emerg Drugs
. 2022 Jun;
27(2):169-185.
PMID: 35749672
Introduction: Despite recent advances in the treatment of adult acute myeloid leukemia (AML), the clinical outcome of patients continues to be unsatisfactory especially among older patients, those with a high-risk...
17.
de Botton S, Montesinos P, Schuh A, Papayannidis C, Vyas P, Wei A, et al.
Blood
. 2022 Jun;
141(2):156-167.
PMID: 35714312
This open-label, randomized, phase 3 trial (NCT02577406) compared enasidenib, an oral IDH2 (isocitrate dehydrogenase 2) inhibitor, with conventional care regimens (CCRs) in patients aged ≥60 years with late-stage, mutant-IDH2 acute...
18.
Zeidan A, Fenaux P, Gobbi M, Mayer J, Roboz G, Krauter J, et al.
Blood
. 2022 May;
140(3):285-289.
PMID: 35507690
No abstract available.
19.
Duployez N, Largeaud L, Duchmann M, Kim R, Rieunier J, Lambert J, et al.
Blood
. 2022 Apr;
140(7):756-768.
PMID: 35443031
DDX41 germline mutations (DDX41MutGL) are the most common genetic predisposition to myelodysplastic syndrome and acute myeloid leukemia (AML). Recent reports suggest that DDX41MutGL myeloid malignancies could be considered as a...
20.
Plesa A, Tigaud I, Hayette S, Roumier C, Thomas X
Oncol Ther
. 2022 Feb;
10(1):75-84.
PMID: 35129793
We report a case of donor-derived leukemia (DDL) occurring 34 months after double-unit cord blood transplantation (CBT). Molecular analysis using short tandem repeat (STR) sequences proved the acute myeloid leukemia...